176.93
price down icon0.10%   -0.17
pre-market  Vorhandelsmarkt:  177.02   0.09   +0.05%
loading
Schlusskurs vom Vortag:
$177.10
Offen:
$177.145
24-Stunden-Volumen:
740.29K
Relative Volume:
0.69
Marktkapitalisierung:
$8.69B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
22.09
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+14.53%
1M Leistung:
+17.79%
6M Leistung:
+7.25%
1J Leistung:
-20.23%
1-Tages-Spanne:
Value
$173.38
$177.57
1-Wochen-Bereich:
Value
$146.26
$184.17
52-Wochen-Spanne:
Value
$91.86
$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
Firmenname
Charles River Laboratories International Inc
Name
Telefon
781-222-6000
Name
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Name
Mitarbeiter
20,100
Name
Twitter
@criverlabs
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CRL's Discussions on Twitter

Vergleichen Sie CRL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
176.93 8.70B 4.06B 413.08M 560.48M 8.01
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
478.32 179.32B 43.21B 6.58B 6.17B 17.29
Diagnostics & Research icon
DHR
Danaher Corp
205.48 145.22B 24.01B 3.41B 4.86B 4.70
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
565.19 44.23B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
199.17 34.14B 15.50B 1.33B 2.16B 7.34
Diagnostics & Research icon
A
Agilent Technologies Inc
120.18 34.19B 6.63B 1.17B 1.19B 4.05

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-09 Hochstufung Citigroup Neutral → Buy
2025-05-23 Hochstufung Redburn Atlantic Neutral → Buy
2025-05-14 Hochstufung TD Cowen Hold → Buy
2025-05-08 Hochstufung Evercore ISI In-line → Outperform
2025-03-21 Herabstufung Goldman Buy → Neutral
2025-03-04 Hochstufung Citigroup Sell → Neutral
2025-03-03 Hochstufung Redburn Atlantic Sell → Neutral
2025-01-22 Herabstufung William Blair Outperform → Mkt Perform
2025-01-17 Herabstufung UBS Buy → Neutral
2024-11-18 Herabstufung CLSA Hold → Underperform
2024-11-07 Hochstufung CLSA Underperform → Hold
2024-10-23 Eingeleitet CLSA Underperform
2024-10-14 Eingeleitet Redburn Atlantic Sell
2024-10-07 Herabstufung Evercore ISI Outperform → In-line
2024-10-02 Herabstufung BofA Securities Buy → Neutral
2024-10-01 Herabstufung Citigroup Neutral → Sell
2024-08-08 Herabstufung JP Morgan Overweight → Neutral
2024-08-08 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-28 Herabstufung Argus Buy → Hold
2024-06-07 Eingeleitet Mizuho Neutral
2024-06-06 Eingeleitet Goldman Buy
2024-02-15 Herabstufung Guggenheim Buy → Neutral
2023-09-13 Eingeleitet TD Cowen Market Perform
2023-07-10 Herabstufung Citigroup Buy → Neutral
2023-02-23 Hochstufung Guggenheim Neutral → Buy
2023-01-12 Herabstufung Jefferies Buy → Hold
2022-09-30 Hochstufung Jefferies Hold → Buy
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-08-04 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-05-24 Eingeleitet Guggenheim Neutral
2022-04-25 Herabstufung Jefferies Buy → Hold
2022-04-07 Eingeleitet Stephens Overweight
2022-02-17 Bestätigt BofA Securities Buy
2022-02-17 Hochstufung Citigroup Neutral → Buy
2022-02-17 Bestätigt Deutsche Bank Buy
2022-02-17 Bestätigt Morgan Stanley Overweight
2022-02-17 Bestätigt UBS Buy
2021-08-05 Fortgesetzt Credit Suisse Neutral
2020-12-16 Herabstufung Citigroup Buy → Neutral
2020-09-10 Hochstufung Jefferies Hold → Buy
2020-07-01 Hochstufung BofA Securities Neutral → Buy
2020-05-13 Hochstufung UBS Neutral → Buy
2020-04-21 Herabstufung Jefferies Buy → Hold
2020-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-02 Eingeleitet Deutsche Bank Buy
2020-02-18 Hochstufung Wolfe Research Peer Perform → Outperform
2020-01-10 Hochstufung Goldman Neutral → Buy
2020-01-08 Eingeleitet Wells Fargo Overweight
2020-01-07 Eingeleitet Citigroup Buy
2019-10-18 Herabstufung BofA/Merrill Buy → Neutral
2019-06-10 Eingeleitet SVB Leerink Outperform
2019-04-30 Fortgesetzt Evercore ISI Outperform
2018-12-14 Eingeleitet Deutsche Bank Buy
2018-10-09 Eingeleitet UBS Neutral
2018-08-23 Hochstufung Raymond James Mkt Perform → Outperform
2018-07-17 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2018-06-15 Hochstufung KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 Hochstufung SunTrust Hold → Buy
Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

pulisher
04:21 AM

How strong is Charles River Laboratories International Inc. company’s balance sheetTriple-digit returns - jammulinksnews.com

04:21 AM
pulisher
03:32 AM

What are Charles River Laboratories International Inc. company’s key revenue driversSky-high profits - jammulinksnews.com

03:32 AM
pulisher
02:18 AM

Is Charles River Laboratories International Inc. a growth stock or a value stockUnlock your portfolio’s hidden potential - jammulinksnews.com

02:18 AM
pulisher
Jul 27, 2025

What institutional investors are buying Charles River Laboratories International Inc. stockRapid wealth creation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is Charles River Laboratories International Inc. a Top Dividend Stock to Watch in 2025Low Risk High Reward Picks - Metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

What catalysts could drive Charles River Laboratories International Inc. stock higher in 2025Breakout stock performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How Charles River Laboratories International Inc. stock reacts to Fed policy changesSmart Money Trade Setups - Metal.it

Jul 27, 2025
pulisher
Jul 27, 2025

How does Charles River Laboratories International Inc. compare to its industry peersGrow your wealth steadily and securely - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

What analysts say about Charles River Laboratories International Inc. stockFree Real-Time Stock Data - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Charles River Laboratories International Inc. stock priceExplosive trading opportunities - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Is Charles River Laboratories International Inc. a good long term investmentHigh-profit capital plays - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Charles River Laboratories International Inc. Stock Analysis and ForecastHigh-yield investments - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Charles River Laboratories Surges 134.22% in Trading Volume, Ranks 365th in Daily Market - AInvest

Jul 24, 2025
pulisher
Jul 24, 2025

RPM International Posts Better-Than-Expected Earnings, Joins ICON, MaxLinear, Nasdaq And Other Big Stocks Moving Higher On ThursdayArrive AI (NASDAQ:ARAI), ASGN (NYSE:ASGN) - Benzinga

Jul 24, 2025
pulisher
Jul 22, 2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Jul 22, 2025
pulisher
Jul 22, 2025

Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development - StreetInsider

Jul 22, 2025
pulisher
Jul 22, 2025

Charles River Labs Stock Rises on Plasmid DNA Deal with Ellys TeamNews and Statistics - IndexBox

Jul 22, 2025
pulisher
Jul 22, 2025

Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Why Are Charles River Laboratories (CRL) Shares Soaring Today - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Why Are Charles River Laboratories (CRL) Shares Soaring Today | Markets | American Financial Group, Inc. - FinancialContent

Jul 22, 2025
pulisher
Jul 22, 2025

Charles River Laboratories Surged 8.6% Intraday—Is This a Game-Changer for Biotech Innovation? - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Here's What to Expect From Charles River Laboratories' Next Earnings Report - MSN

Jul 22, 2025
pulisher
Jul 19, 2025

Is it Prudent to Retain Charles River Stock in Your Portfolio Now? - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

Agree To Purchase Charles River Laboratories International At $150, Earn 21.4% Annualized Using Options - Nasdaq

Jul 18, 2025

Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
diagnostics_research WAT
$302.95
price up icon 1.50%
diagnostics_research DGX
$168.55
price down icon 1.95%
$138.90
price down icon 1.53%
diagnostics_research LH
$264.96
price down icon 1.02%
diagnostics_research MTD
$1,263.99
price up icon 0.26%
diagnostics_research A
$120.18
price down icon 0.14%
Kapitalisierung:     |  Volumen (24h):